Earnings, adjusted for non-recurring costs and amortization costs, came to 74 cents per share. The average estimate of analysts surveyed by Zacks Investment Research was also for earnings of 74 cents per share. The drugstore chain posted revenue of $19.06 billion in the period, exceeding Street forecasts.